Remove Biopharma Remove Leads Remove Networking
article thumbnail

FUJIFILM Diosynth recruits new Quality leader

European Pharmaceutical Review

Maja Pedersen has been appointed as Chief Quality Officer (CQO), to lead FUJIFILM Diosynth Biotechnologies’ global quality team. She explained: “I am thrilled to be joining FUJIFILM Diosynth Biotechnologies again and becoming an integral part of leading our teams to develop and embed a transformational quality culture.” “We

article thumbnail

Sandoz to boost biosimilar development with manufacturing expansion

European Pharmaceutical Review

The company intends to grow its Biopharma Technical Development (BioTD) capabilities and transform the lab building into a state-of-the-art biotech lab by the last quarter of 2023. Sandoz has announced it is investing €25 million in its manufacturing site in Holzkirchen, Germany, to expand its biosimilar development capabilities.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Sandoz mobilises critical medicine production in Europe

European Pharmaceutical Review

Sandoz] has the only major remaining vertically-integrated production network for penicillins in Europe” Penicillins are the leading category of antibiotics worldwide, Sandoz highlighted. Launch of these new facilities help to ensure sustainable access to quality antibiotics and spearhead development of biosimilars, Sandoz noted.

article thumbnail

Enabling the next wave of innovative drug therapies with speciality enzymes

Pharmaceutical Technology

In 2021, Novo Nordisk Pharmatech, a leading pharmaceutical-grade insulin and Quats product supplier announced plans to enter the enzyme market. The impact could be huge for the biopharma industry. Novo Nordisk Pharmatech is excited to support the new modalities at the very forefront of the biopharma industry.

article thumbnail

Call to arms as UK falls back in medicines manufacturing

pharmaphorum

A just-published report from the Medicines Manufacturing Industry Partnership (MMIP) – set up by the UK government and biopharma industry in 2014 to drive growth in the category – says the sector has the potential to be a driver for the UK economy in the next decade.

article thumbnail

6 research and development life sciences predictions for 2023

pharmaphorum

With an early view of market viability, leading companies will be able to monetise new products quickly and at scale across Europe.”. This will enable biopharmas to create a more streamlined drug development process rooted in lean process execution and higher-quality data.”. He leads the global regulatory strategy team.

Safety 111
article thumbnail

Meeting rising demands of a new radiotheranostic era

European Pharmaceutical Review

Compared to the aforementioned copper‑based radionuclides, Cu-64 has a longer production and decay time, which leads to a more expensive production process and a higher radiation burden for the patient. During her career, she held positions of increasing responsibility to lead companies in the field, including AREVA/Framatome.